MedTrace Logo

Urine-DNA Biomarkers in Detecting Bladder Cancer

NCT03066310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2022-11-10

No results posted yet for this study

Summary

DNA biomarkers in urine are important diagnostic and prognostic indicators for bladder cancer. Many genetic alterations have been identified in the urinary DNA. However, not all bladder tumors harbor mutations in the most commonly altered oncogenes. Thus, to reach satisfactory sensitivity and specificity a new diagnostic test should include multiple biomarkers. The investigators will conduct a prospective evaluation of a panel of mutations in urine-DNA test for the detection of urothelial bladder carcinoma in patients with gross hematuria for cystoscope.

Conditions

Interventions

DIAGNOSTIC_TEST

Next generation sequencing

The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.

Sponsors & Collaborators

  • Central South University

    collaborator OTHER

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • Second People's Hospital of Hunan

    collaborator OTHER

  • Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Long Wang, M.D., Ph.D · Xiangya Hospital of Central South Univeristy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2020-01-05
Completion
2020-01-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066310 on ClinicalTrials.gov